As the prevalence of obesity in the United States rises, drugs like Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are receiving more attention. But is GLP-1 an effective option in the long term?
As the prevalence of obesity in the United States rises, drugs like Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are receiving more attention. But is GLP-1 an effective option in the long term?